INTRODUCTION
Swallowing and chewing difficulties are characterised by the inability to safely swallow fluids and /or solid food and are accounting for severe complications, commonly aspiration pneumonia that substantially increases mortality rates. Swallowing and chewing difficulties are more likely to have a neurologic basis and are an important issue in Parkinson's disease (PD).(1) Between 70 to 100% of patients with PD have swallowing and chewing difficulties throughout the disease progression. The prevalence increases proportionally in later stages of the disease. (2) (3) (4) Aspiration pneumonia in the context of swallowing impairment is regarded one of the most important factors contributing to decreased life expectancy of PD patients. In addition, malnutrition, dehydration and medication intake complications are further consequences of swallowing impairment that contribute to significant decline in the quality of patients life. (5) The pathophysiology underlying swallowing and chewing difficulties in PD remains elusive. Several cortical, subcortical and peripheral mechanisms have been partially implicated without a robust and conclusive justification. The swallowing process involves multiple cortical areas, including primary sensorimotor cortex, sensorimotor integration areas, insula, anterior cingulate cortex and the supplementary motor cortex. (6) (7) (8) (9) Swallowing and chewing impairment can also be attributed to brainstem pathology. Notably, early in the course of PD, areas that generate the central swallowing pathway in the medulla (motor nucleus of glossopharyngeal nerve, vagus nerve, reticular activating system) are exposed to the neurodegenerative processes. (10, 11) In addition, the pedunculopontine tegmental nucleus, receives abnormal inhibitory through the pallidum and is thus further exposed to neurodegeneration. (12) In this study we investigated the association of swallowing and chewing impairment and dopaminergic deficits using [ 123 I]FP-CIT single photon emission computed tomography (SPECT). Finally, we explore whether swallowing and chewing difficulties were a predictor of motor symptom progression and cognitive decline.
METHODS

Subjects and clinical evaluation
From the 412 PD patients included in the Parkinson's Progression Markers Initiative underwent both [ 123 I]FP-CIT SPECT assessments, and therefore were integrated in our analytical approach. Among these 398 PD patients, we identified 307 cognitively intact (MoCA≥26), with a complete 60-month follow-up and we included them for the longitudinal analysis. All PD patients were recruited between 2010-2015, diagnosed with PD less than two years prior to a screening visit, never treated with dopamine replacement therapy and presented with two among bradykinesia, resting tremor and rigidity or with asymmetric resting tremor/bradykinesia at screening. following the imaging technical operations manual (http://ppmi-info.org/). Raw SPECT data was acquired into a 128 x 128 matrix stepping each 3 degrees for a total of 120 (or 4 degrees for a total of 90) projections in a window centred on 159±10%KeV. The total scan duration was 30-45 minutes. A Chang 0 attenuation correction was applied using a customised Mu determined empirically from the anthropomorphic brain phantom acquired at each site. A standard Gaussian 3D 6.0mm filter was applied to each image volume and then normalised to standard Montreal Neurologic Institute space. Each scan was interpreted by two independent readers who were blinded to the subjects' demographics and characteristics. For quantification, SPECT image volumes were spatially normalized to an Ioflupane template. The eight most prominent axial slices containing striatum were summed and then a standardized volume of interest (VOI) template was applied to this image. VOI analyses were performed on the left and right caudate and putamen with the occipital region serving as a reference tissue. Specific binding ratios (SBR) were calculated as the ratio of the caudate or putamen VOI count density divided by count density of the occipital cortex minus 1. This measure approximates the binding potential, BP ND , when the tracer is in equilibrium at the target site and was previously reported with Ioflupane SPECT.(14)
Assessment of motor progression and cognitive decline
Motor progression was defined as a change of one point in the H&Y scale at the followup visits. Cognitive decline was defined as having a clinical deterioration of cognitive function reported by the patient or the caregiver, a MoCA score<26 and at least 2 test scores (of six neuropsychological tests indicated above; regardless of the domain tested). Scores should be above 1.5 standard deviation and below the standardized mean scores of education and age. Norms were applied according to current literature (15) .
Follow-up visits took place in the outpatient unit of the reference hospitals once every 6 months and 307 early drug-naïve PD patients were followed up for an average of 60 months.
Standard protocol approvals, registrations, and patient consents.
This study is registered with ClinicalTrials.gov (No: NCT01141023). Each PPMI site has received approval from an ethical committee on human experimentation before the study's initiation. Written informed consent for research was obtained from all individuals participating in the study. The present study was performed according to the STROBE guidelines. (15) 
Statistical analysis
Statistical analysis and graph illustration were performed with SPSS (version 20) and
GraphPad Prism (version 6.0c) for MAC OS X, respectively. For all variables, variance homogeneity and Gaussianity were tested with Kolmogorov-Smirnov test.
Multivariate analysis of variance (MANOVA) was used to assess the main differences in clinical, imaging and non-imaging parameters between PD patients with and without swallowing and chewing difficulties. If the overall multivariate test was significant, Pvalues for each variable were calculated following Bonferroni's multiple comparisons test. Categorical variables are expressed as proportions and compared using the χ2 test.
We interrogated correlations between the swallowing and chewing scores and imaging data using Spearman's rank correlation. To explore whether swallowing and chewing impairment can predict motor disease burden and cognitive dysfunction, Cox proportional hazards analyses were carried out. The time to occurrence of the first event for a given subject was used in the Cox model. All data are presented as mean ± standard deviation (SD), and the level α was set for all comparisons at P<0.05, corrected.
RESULTS
Clinical characteristics
The prevalence of swallowing and chewing difficulties in the cohort of early drug-naïve PD patients was 12.3% (49/398). No significant differences were observed for demographic characteristics (age: P>0.1, gender: P>0.1, disease duration: P>0.1 and family history of PD: P>0.1) between the two groups.
Swallowing and chewing difficulties were more common in early drug-naïve PD patients with akinetic-rigid motor phenotype (34/49; 69.4% vs 207/349; 59.3%).
However, no significant difference was observed in H&Y stage (P>0.1), MDS-UPDRS-III (P>0.1), bradykinesia (P>0.1), rigidity (P>0.1), axial (P>0.1) and resting tremor (P>0.1) subscores between early drug-naïve PD patients with and without swallowing and chewing difficulties ( Table 1) . Early drug-naïve PD patients with swallowing and chewing difficulties had significant higher burden in motor aspects of daily living as measured by the MDS-UPDRS-II (P<0.001).
Early drug-naïve PD patients with swallowing and chewing difficulties had greater nonmotor symptoms burden compared to those without swallowing and chewing difficulties. In specific, early drug-naïve PD patients with swallowing and chewing difficulties had higher MDS-UPDRS-I scores (P<0.001), worse autonomic dysfunction symptoms (SCOPA-AUT; P<0.001), depressive symptoms (GDS; P<0.001), excessive daytime sleepiness (ESS; P<0.001) and RBD (RBDQ; P=0.016) compared to PD patients without swallowing and chewing difficulties ( Table 1) . No significant differences were found in anxiety (STAI; P>0.1), cognitive function (MoCA; P>0.1), olfactory dysfunction (UPSIT; P>0.1) and disability scores (ADL; P=0.336) between early drug-naïve PD patients with and without speech and chewing difficulties. and caudate (rho=−0.156; P=0.002: Figure 2 ).
Imaging assessment: presynaptic dopaminergic function
Motor progression and cognitive decline
Over a period of three years, 180/355 (50.7%) drug-naïve PD patients showed motor progression and 51/307 (16.6%) of them developed cognitive impairment. Cox proportional hazards analysis showed that the presence of swallowing and chewing difficulties in early drug-naïve PD patients has no influence on cognitive decline at the follow-up (Hazard Ratio (HR): 1.735, 95% Confidence Interval (CI): 0.890-3.381; P=0.106) or motor progression (HR: 1.259, 95% CI: 0.830-1.907; P=0.278).
DISCUSSION
Our findings indicate that early drug-naïve PD patients with swallowing and chewing difficulties have greater presynaptic dopaminergic dysfunction in the caudate and nonmotor symptoms burden. Moreover, the loss of striatal dopaminergic function is correlated with swallowing and chewing difficulties in early drug-naïve PD patients.
Finally, swallowing and chewing difficulties are not associated with motor progression or an increased risk of cognitive dysfunction at the follow-up in early drug-naïve PD patients.
The prevalence of swallowing and chewing difficulties in the general PD patients' population ranges between 9 to 77%. (16) We found that swallowing difficulties occur in 12.3% (49/398) of early drug-naïve PD patients and are more frequent in akineticrigid phenotype. This is the first study to report the prevalence of swallowing and chewing difficulties in early drug-naïve PD.
Early drug-naïve PD patients with swallowing and chewing difficulties had increased non-motor symptom burden suggesting a close association between swallowing abnormalities and PD non-motor features. Among the non-motor symptoms, early drug-naïve PD patients with swallowing and chewing difficulties showed worse autonomic dysfunction, depressive symptoms, excessive daytime sleepiness and disordered REM sleeping behaviour. On the contrary, anxiety, cognition, olfactory dysfunction and disability did not differ between the two groups. A recent study has underlined that patients with swallowing and chewing impairment are prone to affective symptomatology such as depression and fear. (18) A recent study suggested that cognitive impairment (frontal/executive and learning/memory) is frequently corelated with the oral phase of swallowing in early PD patients. (19) However, we did not find any alterations in cognitive functions among early drug-naïve PD patients with and without swallowing difficulties. Moreover, swallowing and chewing dysfunction at baseline did not increase the possibilities of harbouring cognitive decline at the follow-up visits.
Furthermore, early drug-naïve patients with PD and swallowing and chewing impairment had substantially decreased striatal [ 123 I]FP-CIT levels when compared to patients without swallowing impairment. The decrease of striatal presynaptic dopaminergic function was associated with the degree of swallowing impairment. To the best of our knowledge, this is the first time which striatal presynaptic dopamine deficits were associated with the degree of swallowing and chewing difficulties in PD.
We found that early drug-naïve PD patients with swallowing and chewing deficits had the greater loss of dopaminergic nigrostriatal terminals in striatum and specifically in caudate.
The functional capacity of the supramedullary network controlling swallowing is depended on the in the integrity of dopaminergic neurons in the basal ganglia. Thus, motor features of PD become apparent. Following the ascending fashion of spreading, it would be expected that due to the early involvement of brainstem areas controlling swallowing, relevant symptoms would be evident in the early stages of the disease. Alas, severe swallowing difficulties are commonly present in advanced PD
patients.
This inconsistency could be explained in the context of activation of compensatory mechanisms in cortical areas in early stages of PD. Using whole-head magnetoencephalography, it has been shown that cortical processing in PD patients without swallowing difficulties harbours a marked alteration of peak activity regarding lateral regions of premotor, motor, and inferolateral parietal cortex. Furthermore, the activity is activity is reduced in the supplementary motor cortex. Interestingly, PD patients with swallowing problems did not exhibit similar activity. These results are indicative of an adaptive mechanism with parallel motor networks, aiming to avoid swallowing dysfunction. However, when neurodegeneration exceeds a certain threshold, clinical symptoms of dysphagia might arise.
The absence of instrumental swallowing examination (i.e. Fibreoptic Endoscopic Evaluation of Swallowing and Videofluoroscopic Swallowing Study) as a validated way to assess swallowing impairment is a limitation of our study. Nevertheless, the use of the clinician-based scale such as the MDS-UPDRS-II (Chewing and Swallowing) item 2.3 may provide a simple tool for clinicians to assess the progression of swallowing difficulties. Finally, the limitation of our study is the correlational approach that does not allow us to perform direct attributions and conclude on causality.
Therefore, our findings need to be interpreted with the appropriate caution.
In conclusion, our results indicate a significant correlation between swallowing difficulties and loss of striatal dopaminergic function in early drug-naïve PD patients.
This specific subgroup of PD patients harbours a substantial burden of non-motor symptoms, without profound motor symptomatology. 
